Table 5.

Pathologic complete response rates in 102 patients whose PIK3CA mutation status was available before and after neoadjuvant chemotherapy

SubgroupTotal (n)Non-pCR, n (%)pCR, n (%)Pa
 mt-mt1515 (100.0)0 (0.0)0.042
 wt-wt7866 (84.6)12 (15.4)
 mt-wt96 (66.7)3 (33.3)
Total10287 (85.3)15 (14.7)
  • amt-mt compared with mt-wt.